340B Drug Pricing Program
In 1990, Congress enacted the Medicaid Rebate Program, as part of the Omnibus Reconciliation Act of 1990 (Pub. L. No. 101-508).20. This law requires drug companies that choose to participate in Medicaid to give states, which administer Medicaid, discounts comparable to those given to other payers.
Tax-exempt hospitals are required to publicly report on the ways in which they improve the health of the communities they serve yearly through the IRS Form 990 Schedule H, which is publicly available. In 2018, the most recent year for which this information is available, tax-exempt hospitals…
The AHA last week urged congressional leaders to provide temporary relief for any hospitals participating in the 340B Drug Pricing Program that had to leave the program due to changes in their patient mix as a result of the COVID-19 pandemic.
The AHA today urged the Supreme Court of the United States to reverse the 2020 federal appeals court decision that upheld the authority of the Department of Health and Human Services to significantly cut payments to certain hospitals that participate in the 340B Drug Pricing Program.
The AHA urged The Supreme Court of the United States to reverse the 2020 federal appeals court decision that upheld the authority of the Department of Health and Human Services to significantly cut payments to certain hospitals that participate in the 340B Drug Pricing Program.
The Centers for Medicare & Medicaid Services July 19 released its calendar year 2022 outpatient prospective payment system/ambulatory surgical center proposed rule.
CMS Issues Hospital Outpatient/ASC Proposed Rule, Including Modifications to Price Transparency Rule
Download the AHA Special Bulletin:
CMS Issues Hospital Outpatient/ASC Proposed Rule,
Including Modifications to Price Transparency Rule
Congress is currently considering legislation that would provide temporary relief for any hospitals participating in the 340B program that had to leave the program due to patient mix changes as a result of the COVID-19 pandemic.
Congress is currently considering legislation that would provide temporary relief for any hospitals participating in the 340B program that had to leave the program due to changes in their patient mix as a result of the COVID-19 pandemic.
The Supreme Court of the United States today decided to take up AHA’s petition asking to reverse a federal appeals court decision that significantly cuts payments to certain hospitals that participate in the 340B Drug Pricing Program, threatening access to care in communities.